Literature DB >> 15958562

Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe.

Diane R Wonsey1, Maximillian T Follettie.   

Abstract

Expression of the forkhead transcription factor FoxM1 correlates with proliferative status in a variety of normal and transformed cell types. Elevated expression of FoxM1 has been noted in both hepatocellular carcinoma and basal cell carcinoma. However, whether FoxM1 expression is essential for the viability of transformed cells is unknown. We report here that the expression of FoxM1 is significantly elevated in primary breast cancer. Microarray analysis shows that FoxM1 regulates genes that are essential for faithful chromosome segregation and mitosis, including Nek2, KIF20A, and CENP-A. Loss of FoxM1 expression generates mitotic spindle defects, delays cells in mitosis, and induces mitotic catastrophe. Time-lapse microscopy indicates that depletion of FoxM1 generates cells that enter mitosis but are unable to complete cell division, resulting in either mitotic catastrophe or endoreduplication. These findings indicate that FoxM1 depletion causes cell death due to mitotic catastrophe and that inhibiting FoxM1 represents a therapeutic strategy to target breast cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15958562     DOI: 10.1158/0008-5472.CAN-04-4059

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  163 in total

1.  FoxM1 mediates resistance to herceptin and paclitaxel.

Authors:  Janai R Carr; Hyun Jung Park; Zebin Wang; Megan M Kiefer; Pradip Raychaudhuri
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

2.  Recovery from a DNA-damage-induced G2 arrest requires Cdk-dependent activation of FoxM1.

Authors:  Mónica Alvarez-Fernández; Vincentius A Halim; Lenno Krenning; Melinda Aprelia; Shabaz Mohammed; Albert J Heck; René H Medema
Journal:  EMBO Rep       Date:  2010-04-09       Impact factor: 8.807

3.  Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma.

Authors:  Shahab Uddin; Azhar R Hussain; Maqbool Ahmed; Khawar Siddiqui; Fouad Al-Dayel; Prashant Bavi; Khawla S Al-Kuraya
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

4.  The Forkhead transcription factor Hcm1 regulates chromosome segregation genes and fills the S-phase gap in the transcriptional circuitry of the cell cycle.

Authors:  Tata Pramila; Wei Wu; Shawna Miles; William Stafford Noble; Linda L Breeden
Journal:  Genes Dev       Date:  2006-08-15       Impact factor: 11.361

5.  FoxM1 involvement in astrocyte proliferation after spinal cord injury in rats.

Authors:  Shuangwei Zhang; Honglin Teng; Qiulei Ding; Jinpeng Fan; Wanying Shi; Yan Zhou; Chunwu Zhang
Journal:  J Mol Neurosci       Date:  2013-02-06       Impact factor: 3.444

6.  β-Trcp ubiquitin ligase and RSK2 kinase-mediated degradation of FOXN2 promotes tumorigenesis and radioresistance in lung cancer.

Authors:  Jia Ma; Yanwei Lu; Sheng Zhang; Yan Li; Jing Huang; Zhongyuan Yin; Jinghua Ren; Kai Huang; Li Liu; Kunyu Yang; Gang Wu; Shuangbing Xu
Journal:  Cell Death Differ       Date:  2018-02-02       Impact factor: 15.828

7.  NOSH-aspirin (NBS-1120) inhibits pancreatic cancer cell growth in a xenograft mouse model: Modulation of FoxM1, p53, NF-κB, iNOS, caspase-3 and ROS.

Authors:  Mitali Chattopadhyay; Ravinder Kodela; Gabriela Santiago; Thuy Tien C Le; Niharika Nath; Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2020-02-14       Impact factor: 5.858

Review 8.  Playing polo during mitosis: PLK1 takes the lead.

Authors:  G Combes; I Alharbi; L G Braga; S Elowe
Journal:  Oncogene       Date:  2017-04-24       Impact factor: 9.867

9.  Global analysis of genes regulated by HOXA10 in decidualization reveals a role in cell proliferation.

Authors:  Z Lu; J Hardt; J J Kim
Journal:  Mol Hum Reprod       Date:  2008-05-02       Impact factor: 4.025

Review 10.  Basal cell carcinomas: attack of the hedgehog.

Authors:  Ervin H Epstein
Journal:  Nat Rev Cancer       Date:  2008-10       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.